Ratha-korn Vilaichone MD, Ph.D, FACG, AGAF
ProfessorThailand
The agenda for this LIVE webinar includes a 40-minute presentation on "Recent Updates in Management of H. pylori: Eradication in the Era of Antibiotic Resistance" and a 20-minute Q&A session with Professor Ratha-korn Vilaichone.
A recent study showed that more than four billion people were estimated to be infected with Helicobacter pylori worldwide. H. pylori infection causes many gastrointestinal diseases, such as peptic ulcer, chronic gastritis, gastric cancer, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
The recommended first-line eradication regimen was proton pump inhibitor (PPI)-based triple therapy, consisting of a PPI plus amoxicillin and clarithromycin or metronidazole. However, the eradication rate of PPI-based triple therapy has been declining in recent years, owing to increased H. pylori resistance to clarithromycin and metronidazole. In many parts of Asia, H. pylori resistance rates for clarithromycin and metronidazole reach more than 50%.
Bismuth-containing quadruple therapy and concomitant therapy are recommended as first-line options in many parts of Asia where the prevalence of primary clarithromycin resistance is >15%. Adding to the armamentarium, we have Vonoprazan, a novel oral acid suppressant, which, like PPIs, belongs to a group of H+-K+ ATPase inhibitors with more potent acid suppression ability.
In this presentation, we will review some of the latest updates on Helicobacter pylori eradication and evidence on the effectiveness of novel acid-suppressant therapies in treatment of H. pylori with antibiotic resistance.
Professor Ratha-korn Vilaichone received his MD, Ph.D (Medicine) and post graduate training in internal Medicine and Gastroenterology from Chulalongkorn University, Bangkok, Thailand and continued his training as postdoctoral fellowship at Baylor College of Medicine, Houston, USA by International Training Grant of American College of Gastroenterology (ACG). Professor Vilaichone was also a Secretary General of Gastroenterology Association of Thailand (GAT) in 2014-2016. Currently, Professor Vilaichone is a Secretary General of Digestive Diseases Research Center (DRC) of Thammasat University Hospital, Thailand and Vice Dean, Research affair and Innovation, Chulabhorn International College of Medicine (CICM), Thammasat University, Thailand.
Professor Vilaichone’s research interests consist of H. pylori infection, Microbiota, Gastric cancer, GERD, NSAIDs, GI bleeding and Hepatocellular carcinima. He has more than 100 local and international publications and received 31 academic awards. He is a reviewer for many scientific journals such as the American Journal of Gastroenterology, European Medical Journal, Canadian Journal of Gastroenterology and Hepatology, Journal of Gastroenterology and Hepatology, Plos one and Helicobacter. In addition, Professor Vilaichone is a fellow of American College of Gastroenterology (FACG) and American Gastroenterology Association (AGAF).
To access this presentation, please login and click on the 'ENROLL TO WATCH' blue button by the right, on this page. To create a new account, please click here.
